8-K - BridgeBio Pharma, Inc. | StockGist

Current Report Details

Event Type

Material Agreement

Financing

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry into a Material Definitive Agreement Royalty Interest Purchase and Sale Agreement On June 27, 2025 (the “Closing Date”), BridgeBio Pharma, Inc. (the “Co

Material Agreement

$300.0M$500.0M

2.03

. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 abov

Financing

Exhibits (1)

8-K